{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:12:48Z","timestamp":1761109968118},"reference-count":4,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,4,15]]},"DOI":"10.1097\/qai.0b013e3181cdebb1","type":"journal-article","created":{"date-parts":[[2010,3,18]],"date-time":"2010-03-18T09:34:33Z","timestamp":1268904873000},"page":"614-618","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy, Safety, and Tolerability of Etravirine With and Without Darunavir\/Ritonavir or Raltegravir in Treatment-Experienced Patients: Analysis of the Etravirine Early Access Program in the United States"],"prefix":"10.1097","volume":"53","author":[{"given":"William","family":"Towner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Lalezari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G","family":"Sension","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Wohlfeiler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Gathe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan S","family":"Appelbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Bellman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Nijs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemie","family":"Hoogstoel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodica","family":"Van Solingen-Ristea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Witek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R5-8-20210131","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1128\/AAC.00487-08","article-title":"Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.","volume":"52","author":"Anderson","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R6-8-20210131","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1097\/QAD.0b013e3283316a5e","article-title":"Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.","volume":"23","author":"Katlama","year":"2009","journal-title":"AIDS"},{"key":"R7-8-20210131","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/QAD.0b013e32831c5040","article-title":"Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a Phase IIb trial.","volume":"23","author":"Cohen","year":"2009","journal-title":"AIDS"},{"key":"R8-8-20210131","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1086\/591705","article-title":"Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a Phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection.","volume":"47","author":"Montaner","year":"2008","journal-title":"Clin Infect Dis"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QAI.0b013e3181cdebb1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:51:23Z","timestamp":1620971483000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-201004150-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,15]]},"references-count":4,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e3181cdebb1","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4,15]]}}}